Indoleamine 2,3-dioxygenase (IDO) Activity in Patients With Chronic Lymphocytic Leukemia (CLL) (KLL3)
The Activity of Indoleamine 2,3-dioxygenase in patients with Chronic Lymphocytic Leukemia (CLL) is studied.
|Study Design:||Observational Model: Case Control
Time Perspective: Prospective
|Official Title:||The Activity of Indoleamine 2,3-dioxygenase in Patients With Chronic Lymphocytic Leukemia (CLL)|
- IDO activity and expression measured by kynurenine/tryptophan ratio in serum and by PCR in peripheral blood mononuclear cells. [ Time Frame: 3 months ] [ Designated as safety issue: No ]Indoleamine 2,3 -dioxygenase (IDO) activity in patients with CLL was measured by the serum kynurenine/tryptophan (kyn/trp) ratio and - the expression of INDO (encoding IDO enzyme) and INDOL1 (encoding IDO2 enzyme) genes in peripheral blood mononuclear cells via TaqMan real-time PCR.
Biospecimen Retention: Samples With DNA
|Study Start Date:||February 2010|
|Study Completion Date:||December 2010|
|Primary Completion Date:||December 2010 (Final data collection date for primary outcome measure)|
The Activity of Indoleamine 2,3-dioxygenase in patients with Chronic Lymphocytic Leukemia (CLL)is studied in patients and healthly controls.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01397916
|Tampere university Hospital|
|Tampere, Finland, 33521|
|Principal Investigator:||Marjatta Sinisalo, MD, PhD||Tampere University Hospital|